Sionna Therapeutics Reports First Quarter 2026 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Sionna Therapeutics Reports First Quarter 2026 Financial Results

Guggenheim on Sionna Therapeutics (SION): 'We think these readouts are highly meaningful catalysts for the company'

May 12, 2026 12:20 PM EDT

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $50.00 price target on Sionna Therapeutics (NASDAQ: SION).

The analyst comments "This morning, SION announced 1Q26 earnings. The company ended 1Q26 with $289.9MM in cash and guided cash runway until 2028. Key updates are: (1) Phase IIa PreciSION study (n~16) has recently completed patient enrollment, and the company has reiterated topline readout guidance for summer 2026 (we think around... More